5 recruiting, 4 unknown, 3 completed, 1 active not recruiting. 15 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Recruiting 5, Unknown 4, Completed 3, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Anthracyclines: new trials by email Literature Review of Anthracyclines trials Research Report on Anthracyclines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SA+X in the Treatment of Newly Diagnosed AML Anthracycline, Ivosidenib, Gilteritinib - Acute Myeloid Leukemia | Phase 2 | Recruiting | Ruijin Hospital | 205 | 2026-05-01 | 2026-07-30 |
| Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker 5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days - Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML) | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 112 | 2026-04-09 | 2026-10-08 |
| Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer SHR-A1811, Adebrelimab (PD-L1 inhibitor), Taxane Chemotherapy - Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 249 | 2026-02-15 | 2026-01-05 |
| Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer Posaconazole, Nab-paclitaxel, Carboplatin - Breast Cancer | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 72 | 2025-05-01 | 2026-02-25 |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer Organoid-guided treatment, Taxane, Capecitabine - HER2-negative Breast Cancer, Advanced Breast Cancer | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 252 | 2024-10-01 | 2024-11-25 |
| A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC Nab paclitaxel/Carboplatin, anthracyclines,Tislelizumab - Breast Cancer (Triple Negative Breast Cancer (TNBC)), Chemeotherapy | Phase 2 | Completed | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 36 | 2024-10-01 | 2026-09-18 |
| Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML Chidamide, Venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 240 | 2024-08-21 | 2025-11-17 |
| AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer AT regimen, TP regimen - HER2-negative Breast Cancer | Phase 2 | Unknown | Sichuan Provincial People's Hospital | 100 | 2020-08-01 | 2020-08-05 |
| HDM201 Added to CT in R/R or Newly Diagnosed AML HDM201, cytarabine, anthracycline - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2019-11-15 | 2020-01-09 | |
| Histological Response Rate After Mastectomy and Immediate Breast Reconstruction at the End of Neoadjuvant Chemotherapy and Radiotherapy Immediate mammary reconstruction, Chemotherapy, Radiation therapy - Breast Cancer | Phase 2 | Unknown | Institut Paoli-Calmettes | 101 | 2016-01-27 | 2023-07-03 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer AZD2014, AZD4547, AZD5363 - Metastatic Breast Cancer | Phase 2 | Active not recruiting | UNICANCER | 1460 | 2014-04-07 | 2025-01-15 |
| Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms Induction Chemotherapy, Consolidation Chemotherapy, Autologous Stem Cell Transplantation - Acute Myeloid Leukemia, Myeloproliferative Neoplasms | Phase 2 | Completed | Hospital Israelita Albert Einstein | 455 | 2012-10-01 | 2016-11-08 |
| Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer Liposomal doxorubicin hydrochloride, Cyclophosphamide, Trastuzumab - Breast Cancer | Phase 2 | Completed | Cephalon, Inc. | 126 | 2008-10-13 | 2024-02-23 |
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Anthracyclines, liposomal daunorubicin, 2-CDA - Myeloid Leukemia | Phase 2 / Phase 3 | Unknown | University Hospital Muenster | 550 | 2004-03-01 | 2012-05-23 |
| GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL. High-dose anthracycline - Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 1996-10-01 | 2018-10-23 |
Breast Neoplasms (6) · Leukemia, Myeloid, Acute (6) · Leukemia (3) · Triple Negative Breast Neoplasms (2) · Anemia, Refractory, with Excess of Blasts (1) · Leukemia, Myeloid (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Neoplasm, Residual (1) · Polycythemia Vera (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1)
Guangdong Provincial People's Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Cephalon, Inc. (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hospital Israelita Albert Einstein (1) · Institut Paoli-Calmettes (1) · Novartis Pharmaceuticals (1) · Ruijin Hospital (1) · Shandong Cancer Hospital and Institute (1) · Sichuan Provincial People's Hospital (1) · The Methodist Hospital Research Institute (1) · UNICANCER (1) · University Hospital Muenster (1)
China (7) · France (3) · Germany (2) · Austria (1) · Belgium (1) · Brazil (1) · Italy (1) · Spain (1) · United States (1)
Dirk Reinhardt, Prof. Dr. med. (1) · Fabio P Santos, MD (1) · Franco Mandelli, Prof. (1) · Jianyu Weng (1) · Nelson Hamerschlak, MD, PhD (1) · Shilpan Shah, MD (1) · Ursula Creutzig, Prof. Dr. med. (1)
PMID 18083847, PMID 18182574, PMID 21480469, PMID 23704089, PMID 26814618, PMID 27269945, PMID 32067679, PMID 34048072, PMID 40803346, PMID 41366419
2008 (1), 2018 (1)